CNBC host Jim Cramer does not appear enthused about the historic win for organized labor that occurred on Friday when an Amazon warehouse in Staten Island voted to unionize.
While discussing the victory on CNBC, Cramer complained that Amazon will no longer be allowed to order their workers at the Staten Island warehouse to show up whenever they're needed.
"If you can't tell your employees when they work, then you're really not able to have much of an ability to move product," he said. “The unions will be in charge of time that you need to work, and that would be dreadful!"
Cramer did acknowledge unions do exist in other companies and that those companies are still profitable, but he then pivoted back to griping about unions being able to set schedules for workers.
"No one wants to work certain shifts," he said. "So you can just say, 'Listen I'm not going to work that shift.' And Amazon would not be able to say, 'Yes you must work it!' So that's what's at stake with unions."
Cramer also added that "one reason why Amazon works so well is that people must work when Amazon says you must work."
Watch the video below.
Jim Cramer melting down over Amazon union victory: \u201cThe unions will be in charge of time that you need to work, and that would be dreadful\u201dpic.twitter.com/S5slLQPPp5— Ken Klippenstein (@Ken Klippenstein) 1648849892
On Thursday night, June 1, economists all over the world breathed a huge sigh of relief when the U.S. Senate, in a 63-36 vote, passed a bill raising the country's debt ceiling. The bill, which had passed 314-117 in the U.S. House of Representatives on May 31, has been sent to President Joe Biden to be signed into law.
U.S. Treasury Secretary Janet Yellen had been sounding the alarm and warning that the United States would begin to default on its debt obligations as soon as Monday, June 5 — a default that, Yellen emphasized, would set off an "economic and financial catastrophe." According to Yellen and countless economists, a default would have had dire economic consequences not only for the U.S., but for other countries as well.
It took a lot of negotiating, but President Joe Biden and House Speaker Kevin McCarthy (R-California) worked out a budget/debt ceiling agreement that passed in the House before going to the Senate for consideration. Senate Majority Leader Chuck Schumer (D-New York) and Senate Minority Leader Mitch McConnell (R-Kentucky) came to a bipartisan understanding as well, and they were able to get enough members of their caucuses on board for it to pass.
According to Politico reporters Burgess Everett and Jennifer Haberkorn, two centrists who played influential behind-the-scenes roles in the battle to get a debt ceiling bill passed were Sen. Kyrsten Sinema (I-Arizona) and Sen. Joe Manchin (D-West Virginia).
In an article published on June 2, Everett and Haberkorn report, "Many people in Washington were surprised when May's debt ceiling negotiations quickly narrowed down to House Speaker Kevin McCarthy, his lieutenants and top White House aides. Not Sen. Kyrsten Sinema (I-Ariz.). In fact, it was sort of her idea…. The deal was pretty much exactly where the two senators hoped everything would end up — alienating only the far right and left and empowering the center."
Sinema, a former Democrat turned independent, doesn't give a lot of interviews. But she spoke to Politico, saying, "I did suggest to the White House that meetings would be more productive if the people who actually had the authority to make a deal and deliver the votes were the only ones in the room."
Manchin, meanwhile, told Politico, "It's a wonderful deal when you have the extremes back in the minority."
Sinema, according to Everett and Haberkorn, "leaned on years of relationships with McCarthy and lead negotiators Reps. Garret Graves (R-La.) and Patrick McHenry (R-N.C.), while also consulting closely with OMB Director Shalanda Young and White House counselor Steve Ricchetti, who led the White House strategy alongside Legislative Director Louisa Terrell."
The Arizona senator, they add, "spent Thursday racing around the Capitol, aiding Senate leaders as they sought an agreement to speed votes up, spending literally hours helping craft joint statements and locking in amendment votes."
Sinema told Politico, "I was talking with everyone all the time."
Politico also asked Sinema if she plans to seek reelection as an independent in 2024. Her response, "I'm not gonna tell you."
Donald Trump congratulated his former Vice President Mike Pence for avoiding charges in his classified document case Friday – then whined that the ongoing investigation into his case is a "Witch hunt."
"Just announced that they are not going to bring charges against Mike Pence on the document hoax," he wrote on his Truth Social platform.
"That’s great, but when am I going to be fully exonerated, I’m at least as innocent as he is. And what about Joe Biden, who is hiding at least 1850 boxes, and some located in Chinatown, DC?
"When will the witch hunt against “TRUMP” stop?
Many analysts believe charges against Trump for holding classified documents in his Mar-a-Lago home are imminent, particularly after most recent reports that special prosecutor Jack Smith has a recording of him talking about a document involving potential attacks on Iran.
About a dozen classified documents had been found in Pence's Indiana home.
Even when the disease is caught early, breast cancer recurrence is relatively commonplace -- and for survivors, the prospect can be daunting.
A drug developed by Swiss pharmaceutical maker Novartis reduced this risk by a quarter in a large group of early-stage survivors of the most common type of breast cancer, according to clinical trial results presented Friday at the American Society of Clinical Oncology's (ASCO) annual meeting, offering patients new hope.
The study of ribociclib, which belongs to a newer class of drugs known as molecularly targeted therapies, was described as a "very important and practice-changing clinical trial," by ASCO expert Rita Nanda, who was not involved in the research.
The majority of the two million new breast cancers diagnosed globally are in the early phases of disease, defined as stages I through III.
"The current standard of therapy for these patients is surgery followed by chemotherapy... or radiation, then followed by between five and 10 years of hormonal blockade by various endocrine therapies," lead author Dennis Slamon of the UCLA Jonsson Comprehensive Cancer Center told reporters.
But recurrence is as high as more than one in three people for stage I, and more than one in two in stage III, with the cancer sometimes returning decades later.
The clinical trial involved more than 5,100 people with stage II and stage III forms of HR-positive, HER2-negative breast cancer, which is the most common subtype, making up nearly 70 percent of all breast cancer cases in the United States.
Half the patients received ribociclib -- marketed under the brand name Kisqali -- as well as hormonal therapy, while the other half received only hormonal therapy. They continued for a treatment period of three years.
But the trial was halted early because a significant difference in outcomes between the two groups became apparent, and it would not have been ethical to allow the hormone therapy-only group to miss out on the more effective treatment.
Overall, 7.4 percent of patients in the ribociclib group experienced a recurrence against 9.2 percent of patients in the hormone therapy-only group, which means an approximate risk reduction of 25 percent.
"Ribociclib also showed more favorable outcomes in overall survival, recurrence-free survival, and distant disease-free survival," a press statement said.
While ribociclib, which is already widely approved around the world, has previously shown benefit for people with metastatic breast cancer, the new study was able to demonstrate it also improves outcomes for people with earlier stages, including those with cancer that hasn't yet spread to the lymph nodes.
The most common side effects were abnormally low counts of a type of white blood cell called neutrophils, as well as joint pain. Less common effects included gastrointestinal issues and fatigue.
Ribociclib works by disrupting proteins in breast cancer cells responsible for cell division.
Novartis plans to continue to study longer-term outcomes.
© Agence France-Presse
Copyright © 2023 Raw Story Media, Inc. PO Box 21050, Washington, D.C. 20009 | Masthead | Privacy Policy | Manage Preferences
For corrections contact corrections@rawstory.com, for support contact support@rawstory.com.
